Examples of using Trabectedin in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
The active substance is trabectedin.
Thus the trabectedin extraction ratio can be considered moderate.
Yondelis 0.25 mg powder for concentrate for solution for infusion Trabectedin.
Trabectedin extravasation may cause tissue necrosis requiring debridement.
Myelosupression and hepatoxicity were identified as the primary toxicity for trabectedin.
Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.
The effects of race and ethnicity on trabectedin pharmacokinetics have not been studied.
Combination of trabectedin with phenytoin or live attenuated vaccines is not recommended and with yellow fever vaccine is specifically contraindicated see sections 4.3 and 4.5.
Yondelis 0.25 mg powder for concentrate for solution for infusion Yondelis 1mg powder for concentrate for solution for infusion Trabectedin.
The patients received the trabectedin dose of 1.2 mg/m2 recommended for Japanese patients 1.2 mg/m2 once every 3 weeks q3wk 24-h.
Embarrassed to the bonemeal mucous edades for 5 to 10venipunctures resulting in daysperitoneal topical acomplia fast ship for thecal trabectedin injection.
In a placebo-controlled QT/QTc study, trabectedin did not prolong the QTc interval in patients with advanced solid malignancies.
Caution should be taken if medicinal products associated with hepatotoxicity are administered concomitantly with trabectedin, since the risk of hepatotoxicity may be increased.
Fertility studies with trabectedin were not performed but limited histopathological changes were observed in the gonads in the repeat dose toxicity studies.
Researchers working with Dawei Ma at the Shanghai Institute of Organic Chemistry(China) have now described a more efficient andviable de novo synthetic route for trabectedin and lurbinectedin.
Of the 333 patients with ovarian cancer who received trabectedin in combination with PLD, 24% were 65 years of age or older and 6% were over 75 years.
Trabectedin works by attaching to the DNA, the chemical molecule that makes up genes, and preventing some genes in human cells from increasing their activity.
Allergic Reactions: During clinical trials, hypersensitivity was reported in 2% of patients receiving trabectedin either alone or in combination with PLD, and most of these cases were Grade 1 or 2 in severity.
Feb-2019 With its vast numbers of different lifeforms, the sea is a largely unexplored source of natural products that could be starting points for new pharmaceuticals,such as the antitumor drugs trabectedin and lurbinectedin.
The active substance in Yondelis, trabectedin, is a synthetic version of a substance that was originally extracted from a species of tunicate or‘sea squirt' a marine animal.
If administration is to be made via a central venous line, add the reconstituted solution to an infusion bag containing≥ 50 ml of diluent(sodium chloride 9 mg/ ml(0.9%) solution for infusion or glucose 50 mg/ ml(5%) solution for infusion),being the concentration of trabectedin in the infusion solution≤ 0.030 mg/ ml.
There is no relevant influence ofrenal function measured by creatinine clearance on trabectedin pharmacokinetics within the range of values(≥ 30.3 ml/min) present in the patients included in the clinical studies.
Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.
The study primary endpoint was PFS, that showed a statistically significant improvement in favour of trabectedin over BSC[HR=0.07; 95% CI: 0.03-0.16; p< 0.0001], with a median PFS in the trabectedin group of 5.6 months[95% CI: 4.1-7.5] and in the BSC group of 0.9 months 95% CI: 0.7-1.0.
If administration is to be made through a central venous line, the appropriate amount of reconstituted solution should be withdrawn from the vial and added to an infusion bag containing 50 ml of diluent(sodium chloride 9 mg/ml(0.9%) solution for infusion or glucose 50 mg/ml(5%) solution for infusion),the concentration of trabectedin in the infusion solution being≤ 0.030 mg/ml.
Using the RECIST criteria the ORR among patients treated with trabectedin was 3(8.1%; 95% CI: 1.7.21.9%) and 0(0%, 95% CI: 0.0-9.7%) among patients treated with best supportive care, while the CBR was 24(64.9%, 95% CI: 47.5-79.9%) versus 0(0%, 95% CI: 0.0-9.7%), respectively.
The efficacy and safety of trabectedin in soft tissue sarcoma is based in a randomised trial in patients with locally advanced or metastatic lipo- or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide.
There are hundreds of examples: antibiotics such as penicillin or erythromycin,anti-tumour drugs such as trabectedin and vinblastine, immunosuppressants such as cyclosporine and rapamycin that facilitate organ transplants, analgesics such as morphine and codeine, and antimalarials such as quinine and artemisinin.
Some potential riskfactors that may have contributed to increased trabectedin toxicity observed in these cases were dose management inconsistent with recommended guidelines, potential CYP3A4 interaction due to multiple competing CYP3A4 substrates or CYP3A4 inhibitors, or lack of dexamethasone prophylaxis.
Additional efficacy data are available from arandomized active-controlled phase III study of trabectedin vs. dacarbazine(Study ET743-SAR-3007), in patients treated for unresectable or metastatic lipo- or leiomyosarcoma who have been previously treated with at least an anthracycline and ifosfamide containing regimen, or an anthracycline containing regimen and one additional cytotoxic chemotherapy regimen.